Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.71 |
| ▸ | IDO1 | P14902 | 4/20 | 0.68 |
| ▸ | CES1 | P23141 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | CES2 | O00748 | 1/20 | 0.68 |
| ▸ | GMNN | O75496 | 1/20 | 0.68 |
| ▸ | TDP2 | O95551 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | NQO1 | P15559 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5940435 | 0.86 | MALT1 (0.75) | MALT1IDO1CES1KDM4EMEN1 | |
| SCHEMBL25704071 | 0.83 | MALT1 (0.71) | MALT1IDO1CES1KDM4EMEN1 | |
| Lapachone SCHEMBL107042 | 0.81 | MALT1 (1.00) | MALT1IDO1CES1KDM4EMEN1 | |
| Lapachone SCHEMBL29351050 | 0.81 | MALT1 (1.00) | MALT1IDO1CES1KDM4EMEN1 | |
| SCHEMBL5940394 | 0.81 | MALT1 (0.74) | MALT1IDO1CES1KDM4EMEN1 | |
| SCHEMBL14439372 | 0.78 | MALT1 (0.90) | MALT1IDO1CES1KDM4EMEN1 | |
| SCHEMBL14456608 | 0.78 | MALT1 (0.71) | MALT1IDO1CES1KDM4EMEN1 | |
| Alpha-Lapachone SCHEMBL102553 | 0.76 | IDO1 (1.00) | MALT1IDO1CES1KDM4EMEN1 | |
| Alpha-Lapachone SCHEMBL29355317 | 0.76 | IDO1 (1.00) | MALT1IDO1CES1KDM4EMEN1 | |
| SCHEMBL14439378 | 0.76 | MALT1 (1.00) | MALT1IDO1CES1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4180034-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | KT & G CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| WO-2009082124-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | MAZENCE INC. (KR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009048251-A2 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2009-04-16 | — | — | WO | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066295-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066301-A1 | ANTICANCER COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066294-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLE OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066297-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066299-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066298-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | REN, ATP6V1B1, SLC5A1 | MALT1 3646/4885IDO1 1624/4885CES1 225/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | MALT1 3696/4885IDO1 217/4885CES1 2582/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | MALT1 4688/4885IDO1 1806/4885CES1 614/4885 |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | NLN, SLC25A20, ACAD9 | MALT1 4454/4885IDO1 3300/4885CES1 336/4885 |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | TNNT2, TNNC1, TNNI3 | MALT1 3298/4885IDO1 2331/4885CES1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.